ZyVersa Therapeutics, Inc.
ZVSA
$0.1221
-$0.0079-6.08%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.02% | -58.75% | 40.79% | 13.11% | 2.23% |
| Total Depreciation and Amortization | -- | -- | -558.82% | -34.62% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.16% | -45.64% | 76.17% | -5.69% | -45.14% |
| Change in Net Operating Assets | 51.54% | 523.27% | -104.90% | 135.63% | 153.57% |
| Cash from Operations | 14.13% | -44.71% | -90.04% | 66.33% | 49.32% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -34.23% | 267.21% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1,447.31% | 63.94% | -126.49% | -- | -- |
| Cash from Financing | -100.96% | -29.62% | 306.39% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,009.93% | -94.28% | 41,311.76% | 100.18% | -73.36% |